Chalcogen Or Nitrogen Bonded Indirectly To The Imidazole Ring By Nonionic Bonding Patents (Class 514/399)
-
Publication number: 20110052703Abstract: Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the beta-casein micelles may be used to administer the agents to the GI tract for treatment of local or systemic conditions. These carriers are stable over a wide temperature range (optionally at least from about 1° C. to at least about 45° C.).Type: ApplicationFiled: February 11, 2009Publication date: March 3, 2011Inventors: Yechezkel Barenholz, Dganit Danino
-
Publication number: 20110053878Abstract: The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods.Type: ApplicationFiled: April 4, 2007Publication date: March 3, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jerry Yang, Seong Deok Kong, Alice Luong, Stephen Howell
-
Process for the Production of Particles Comprising Active Agrochemical Ingredients in Amorphous Form
Publication number: 20110053772Abstract: An object of the present invention is a process for the preparation of particles which comprise two agrochemical active ingredients in amorphous form, where a melt comprising the two molten agrochemical active ingredients is emulsified in an aqueous solution and cooled. A further object is the use of an agrochemical active ingredient for inhibiting the crystallization of another agrochemical active ingredient in a preparation process for particles which comprise the two agrochemical active ingredients in amorphous form, where a melt comprising the two molten agrochemical active ingredients is emulsified in an aqueous solution and cooled. A further object is particles which comprise two agrochemical active ingredients in amorphous form. The use in plant protection is also described.Type: ApplicationFiled: May 6, 2009Publication date: March 3, 2011Applicant: BASF SEInventors: Ulrike Troppmann, Winfried Mayer, Sebastian Koltzenburg, Rafel Israels, Andreas Bauder, Ulf Schlotterbeck -
Patent number: 7897633Abstract: The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.Type: GrantFiled: October 24, 2007Date of Patent: March 1, 2011Assignee: Probiodrug AGInventors: Stephan Schilling, Mirko Buchholz, Andre Niestroj, Ulrich Heiser, Hans-Ulrich Demuth
-
Publication number: 20110046147Abstract: The invention relates to 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) inhibitors, the preparation thereof and the use thereof for the treatment and prophylaxis of hormone-related, especially estrogen-related or androgen-related, diseases.Type: ApplicationFiled: August 22, 2008Publication date: February 24, 2011Applicant: UNIVERSITAT DES SAARLANDESInventors: Rolf Hartmann, Martin Frotscher, Sandrine Oberwinkler, Emmanuel Bey
-
Publication number: 20110039705Abstract: A method of producing a granular agrochemical composition having excellent handling properties, wherein a powdered agrochemical wettable composition or powdered agrochemical water-soluble composition is converted in form to a granular agrochemical composition, without altering the formulation thereof. The method of producing a granular agrochemical composition includes: treating a powdered agrochemical wettable composition or powdered agrochemical water-soluble composition by (1) a step of adding water, kneading, extruding and drying, (2) a step of adding water, granulating by stirring and drying, (3) a step of adding water, kneading and spray-drying, (4) a step of adding water and performing fluidized bed granulation, or (5) a step of pressure molding the powdered agrochemical wettable composition or powdered agrochemical water-soluble composition; followed by (a) a step of performing microgranulation by grinding, and if necessary, (b) a step of performing grain size regulation by sieving.Type: ApplicationFiled: April 23, 2009Publication date: February 17, 2011Inventors: Yoshihisa Endo, Satoru Yamamura
-
Publication number: 20110038932Abstract: Disclosed are methods for treating a subject suffering from phenylketonuria and/or phenylalanemia. The methods include, in part, enterally administering to the subject a LNAA supplement in which the weight ratio of Leu to Val is greater than 2:1; in which the weight ratio of Leu to iLeu is greater than 3:1; or which includes one or more LNAAs and which further includes Lys. LNAA supplements are also disclosed. Also disclosed are methods for treating a subject suffering from a condition involving a metabolic disorder involving the metabolism of a first amino acid X. The method includes enterally administering to the subject a composition which (i) is substantially free from the first amino acid X and (ii) which includes a second amino acid Y that competes with amino acid X at a gastrointestinal tract transporter.Type: ApplicationFiled: August 5, 2010Publication date: February 17, 2011Inventor: Reuben Matalon
-
Publication number: 20110039802Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylone, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereofType: ApplicationFiled: July 2, 2010Publication date: February 17, 2011Inventors: Yasuyuki KAWANISHI, Hideyuki TAKENAKA, Kohji HANASAKI, Tetsuo OKADA
-
Publication number: 20110039906Abstract: There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species.Type: ApplicationFiled: July 18, 2008Publication date: February 17, 2011Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu, Julie Anne Charlton
-
Publication number: 20110039800Abstract: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.Type: ApplicationFiled: July 2, 2010Publication date: February 17, 2011Inventors: Jean-Marc AIACHE, Dominique Costantini, Christine Chaumont
-
Publication number: 20110033402Abstract: The invention relates to a novel solubilized small molecule topical formulation for the transdermal delivery of small molecule agents comprising: a small molecule agent, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the small molecule agent is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation.Type: ApplicationFiled: June 29, 2010Publication date: February 10, 2011Inventor: Pankaj Modi
-
Patent number: 7883716Abstract: A water dispersible granule formulation prepared by pulverized a part of active ingredients into fine particles under wet milling and pulverized another part of the active ingredients into coarse particles under dry milling, then kneading the both active ingredients for the granulation, and a process for producing the water dispersible granule formulation are disclosed. The water dispersible granule formulation according to the present invention is applicable for production of a water dispersible granule formulation comprising an active ingredient which is easily decomposed owing to environmental conditions and allows to provide the water dispersible granule formulation provided with enhanced initial and residual biological activities.Type: GrantFiled: September 25, 2003Date of Patent: February 8, 2011Assignee: Nippon Soda Co., Ltd.Inventor: Masahiro Suzuki
-
Patent number: 7884121Abstract: This invention relates to a process for the preparation of an aminoalkyl phenyl carbamate compound of formula 1, wherein R1 and R2 independently are hydrogen or C1-6 alkyl; R3 and R4 are the same or different and each is a lower alkyl; or R3 and R4 together with the nitrogen to which they are attached form a cyclic moiety of a three to eight-member ring, with or without a hetero atom like nitrogen or oxygen; R5 and R6 independently are hydrogen, linear, branched or cyclic C1-6 alkyl, allyl, propargyl or benzyl; or R5 and R6 together with the nitrogen to which they are attached form a cyclic moiety of three to eight member ring, with or without a hetero atom like nitrogen or oxygen; the carbon center marked with “*” is racemic or enantiomerically enriched (R)- or (S)-configuration; and pharmaceutically acceptable addition salts, and crystalline and amorphous forms thereof comprising the steps of: i) converting an amine R5R6NH to a carbamoylimidazolium salt of formula 3 wherein R5 and R6 areType: GrantFiled: June 11, 2007Date of Patent: February 8, 2011Assignee: Apotex Pharmachem Inc.Inventors: Mohammed Abdul Raheem, Zhi-Xian Wang, Eckardt C. G. Wolf
-
Publication number: 20110028500Abstract: Combinations, compositions and methods of use for modulating plant pathogen infection using plant extracts containing anthraquinone derivatives which induce resistance to plant phytopathogens and an antimicrobial agent, a biological control agent and/or a surfactant having fungicidal activityType: ApplicationFiled: July 29, 2010Publication date: February 3, 2011Applicant: Marrone Bio Innovations, Inc.Inventors: Hai Su, Marja Koivunen, Pamela G. Marrone
-
Publication number: 20110028489Abstract: The present invention relates to a new use of pyrimidine derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment and/or prophylaxis of Alzheimer's Disease:Type: ApplicationFiled: August 16, 2010Publication date: February 3, 2011Inventors: Lars Andersson, Stefan Berg, Jeremy Burrows, Sven Hellberg, Fernando Huerta, Tobias Rein
-
Publication number: 20110028513Abstract: There is presently provided methods for delivering a neuroprotective agent to a neural cell. The methods comprise contacting a neural cell with an imidazolium or imidazolinium compound as described herein, including an imidazolium or imidazolinium salt.Type: ApplicationFiled: March 31, 2009Publication date: February 3, 2011Inventors: Lang Zhuo, Gideon Ho, Yugen Zhang, Jackie Y. Ying
-
Publication number: 20110021377Abstract: The invention refers to the use of a TRPC channel, an inactivating mutant thereof, or a nucleotide sequence coding for the TRPC channel or for the inactivating mutant for the production of a medicament for the treatment of a cardiovascular disease and a method of screening a modulator of the TRPC channel or an inactivating mutant thereof.Type: ApplicationFiled: October 5, 2010Publication date: January 27, 2011Applicant: SANOFI-AVENTISInventor: Carsten STRUEBING
-
Publication number: 20110014127Abstract: Described herein are methods for effectively and accurately measuring a patient response upon administration of one or more drugs to the patient. The methods are more sensitive than current methodologies. Also described herein are compositions comprising an analgesic and a sufficient amount of an antihistamine to enhance the analgesic properties of the analgesic. With respect to these compositions, the methods described herein are useful for evaluating qualities of pain, definite improvement, and one or more bodily functions of a subject afflicted with pain. The compositions described herein are useful in improving the quality of pain in a subject or a bodily function of a subject afflicted with pain or definite improvement of a subject afflicted with pain.Type: ApplicationFiled: January 5, 2009Publication date: January 20, 2011Inventor: Bernard P. Schachtel
-
Publication number: 20110009439Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: February 23, 2010Publication date: January 13, 2011Applicant: AQUINOX PHARMACEUTICALS INC.Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
-
Publication number: 20110003016Abstract: A hair treatment composition comprising a trichogenic material and an anti-dandruff agent.Type: ApplicationFiled: October 23, 2008Publication date: January 6, 2011Inventors: Jason Shaun Burry, Richard Livesey Evans, Graham Andrew Turner
-
Publication number: 20110003823Abstract: The invention provides compositions and methods for treating diseases and conditions, including systemic diseases and conditions, through an intravenous administration of a selective ?-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for ?-2 over ?-1 adrenergic receptors. The amounts of the selective ?-2 adrenergic receptor agonists are substantially lower than the amounts normally used to cause sedation. The compositions preferably include dexmedetomidine.Type: ApplicationFiled: May 26, 2010Publication date: January 6, 2011Inventor: Gerald Horn
-
Publication number: 20110002988Abstract: Provided herein is an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. The orally rapidly disintegrating tablets comprises (1) a granulated product containing imidafenacin or imidafenacin particles, which is or are coated with povidone or a gastric juice-soluble polymer; and (2) a composition containing an excipient and a disintegrating agent, wherein the resulting composition is subjected to compression molding.Type: ApplicationFiled: January 30, 2009Publication date: January 6, 2011Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Ishizaki, Yoshinobu Aoki
-
Publication number: 20100331302Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 8, 2010Publication date: December 30, 2010Applicant: Chemocentryx, Inc.Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
-
Publication number: 20100330138Abstract: Biostable, multipurpose, microbicidal intravaginal devices in the form of rings, ringed-meshes, sponges, or diaphragms for use by women and condoms for use by male partners are provided, wherein each of the devices contains a drug effective in treating a particular vaginal infection, while further exhibiting at least one additional function selected from the group dealing with non-hormonal contraception, management of sexually transmitted diseases, viral infections, and retroviral infections as well as the treatment of cervical cancer.Type: ApplicationFiled: May 11, 2009Publication date: December 30, 2010Inventors: Shalaby W. Shalaby, Georgios T. Hilas
-
Publication number: 20100330148Abstract: Described herein are methods of inhibiting IMPDH type 1, and treating or preventing a disease or disorder (or symptoms thereof) associated with IMPDH type 1, wherein an IMPDH type 1 inhibitor compound is administered to a subject.Type: ApplicationFiled: March 20, 2007Publication date: December 30, 2010Applicant: The Johns Hopkins UniversityInventors: Jun O. Liu, Curtis Robert Chong, David J. Sullivan
-
Patent number: 7858654Abstract: Compounds of the formula I: wherein R1 is optionally substituted imidazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.Type: GrantFiled: December 17, 2008Date of Patent: December 28, 2010Assignee: Roche Palo Alto LLCInventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
-
Patent number: 7858807Abstract: Disclosed is a commercially suitable method for producing a 1-substituted-5-acylimidazole compound. A 1-substituted-5-acylimidazole compound is produced with a high position selectivity by reacting an N-substituted amidine compound or a salt thereof with a ketone compound in the presence of a base.Type: GrantFiled: August 22, 2006Date of Patent: December 28, 2010Assignee: Ube Industries, Ltd.Inventors: Shigeyoshi Nishino, Shuji Yokoyama, Hiroyuki Oda, Yoji Omata, Shinya Takigawa
-
Publication number: 20100324046Abstract: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: June 24, 2008Publication date: December 23, 2010Inventors: Paul Harrington, Richard W. Heidebrecht, JR., Solomon Kattar, Thomas A. Miller, Karin M. Otte, Phieng Siliphaivanh, Paul Tempest, Kevin J. Wilson, David J. Witter
-
Patent number: 7846958Abstract: The use of benzophenones of the formula I in which R is hydrogen or C1-C4-alkyl and Hal is fluorine, chlorine or bromine for controlling Pseudocercosporella herpotrichoides in crop plants is described.Type: GrantFiled: July 11, 2003Date of Patent: December 7, 2010Assignee: BASF SEInventors: Markus Gewehr, Ingo Rose, Bernd Müller, Eberhard Ammermann, Ann Orth, Henry Van Tuyl Cotter
-
Publication number: 20100305081Abstract: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided.Type: ApplicationFiled: August 13, 2010Publication date: December 2, 2010Applicant: MediQuest Therapeutics, Inc.Inventor: Frederick J. Dechow
-
Publication number: 20100297077Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.Type: ApplicationFiled: October 3, 2008Publication date: November 25, 2010Applicant: BIONOMICS LIMITEDInventors: Bernard Luke Flynn, Jonathan Bayldon Baell, Jason Hugh Chaplin, Girmit Singh Gill, Damian Wojciech Grobelny, Andrew John Harvey, Jorgen Alvar Mould, Dharam Paul
-
Publication number: 20100298394Abstract: Provided herein are compounds, compositions and methods for protecting neuronal and glial cells.Type: ApplicationFiled: June 14, 2010Publication date: November 25, 2010Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Joseph P. Steiner, Avindra Nath, Norman Haughey
-
Patent number: 7838531Abstract: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression.Type: GrantFiled: July 25, 2007Date of Patent: November 23, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, The Regents of the University of Michiga, Progeria Research Foundation, Inc., The University of North Carolina at Chapel HillInventors: Leslie B. Gordon, Francis S. Collins, Thomas Glover, Michael W. Glynn, Brian C. Capell, Adrienne D. Cox, Channing J. Der
-
Publication number: 20100291231Abstract: The present invention relates to compositions which, in sprayable or form, are suitable as wound sealants for woody plants. The invention also relates to a method of protecting woody plants from infection with phytopathogenic fungi, in particular ESCA infection, using such wound sealants. These compositions comprise: a) a water-insoluble sealing agent in dissolved or dispersed form, which is selected among film-forming water-insoluble polymers, waxes and their mixtures; b) at least one plant protectant, c) at least one volatile diluent, in particular an aqueous diluent, and, if appropriate, d) at least one nonionic surface-active substance in an amount of from 10 to 100% by weight, in particular 10 to 80% by weight, based on the sealing agent.Type: ApplicationFiled: September 23, 2008Publication date: November 18, 2010Applicant: BASF SEInventors: Reinhold Stadler, Michael Vonend, Erich Birner, Heike Pfistner, Steffen Henkes, Michael Merk, Sven Harmsen, Egon Haden
-
Publication number: 20100286109Abstract: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.Type: ApplicationFiled: July 22, 2010Publication date: November 11, 2010Applicant: ABBOTT LABORATORIESInventors: Michael R. Schrimpf, Kathleen H. Mortell, Diana L. Nersesian, Chih-Hung Lee, Bruce Clapham
-
Publication number: 20100273728Abstract: The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the low pH found in gastric fluid.Type: ApplicationFiled: May 23, 2008Publication date: October 28, 2010Inventors: Kishor M. Wasan, Ellen K. Wasan
-
Publication number: 20100267690Abstract: Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.Type: ApplicationFiled: June 30, 2010Publication date: October 21, 2010Applicant: Piramal Life Sciences LimitedInventors: Bansi LAL, Swati Bal-Tembe, Usha Ghosh, Arun Kumar Jain, Tulsidas More, Anil Ghate, Jacqueline Trivedi, Sapna Parikh
-
Publication number: 20100267665Abstract: The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.Type: ApplicationFiled: July 1, 2010Publication date: October 21, 2010Applicant: TEIKA PHARMACEUTICAL CO., LTD.Inventors: Takahito Kimura, Shigeto Fujishita, Hiroyoshi Kawada
-
Publication number: 20100267678Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: April 16, 2010Publication date: October 21, 2010Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Patent number: 7812047Abstract: The present invention relates to compounds of formula wherein R1, R2, X, Y and Ar are as defined herein and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9).Type: GrantFiled: June 26, 2008Date of Patent: October 12, 2010Assignee: Hoffman-La Roche Inc.Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Publication number: 20100254983Abstract: This invention provides a method for treating obesity in which comprises administering to the subject an antagonist of a receptor for advanced glycation end products (RAGE) in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat obesity in the subject. The present invention also provides a method for treating hyperglycemia and increased cholesterol, insulin, triglyceride and leptin levels comprising administering to the subject an antagonist of RAGE in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat hyperglycemia and lower cholesterol, insulin, triglyceride and leptin levels on the subject.Type: ApplicationFiled: June 6, 2008Publication date: October 7, 2010Inventors: Ann Marie Schmidt, Anthony Ferrante, Fei Song
-
Publication number: 20100256081Abstract: Bioactive, hydroforming luminal liner compositions are formed of high molecular weight crystalline, absorbable copolyesters dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: April 5, 2010Publication date: October 7, 2010Inventors: Shalaby W. Shalaby, Kenneth David Gray, Georgios T. Hilas
-
Publication number: 20100255016Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: April 5, 2010Publication date: October 7, 2010Inventors: Shalaby W. Shalaby, David Ingram, Georgios T. Hilas, Sheila Nagatomi
-
Publication number: 20100240722Abstract: There is provided a fluorine-containing organosulfur compound having an excellent controlling effect m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 5-membered aromatic heterocyclic group; R1 and R3 are independently represent an optionally substituted C1-C4 chain hydrocarbon group, —C(=G)R5, cyano, halogen or hydrogen; R2 and R4 independently represent an optionally substituted C1-C4 chain hydrocarbon group, halogen or hydrogen; Q represents a C1-C5 haloalkyl group containing at least one fluorine, or fluorine; G represents oxygen or sulfur; and R5 represents optionally substituted C1-C4 alkyl, hydroxyl, optionally substituted C1-C4 alkoxy, optionally substituted C3-C6 alkenyloxy, optionally substituted C3-C6 alkynyloxy, amino, optionally substituted C1-C4 alkylamino, optionally substituted di(C1-C4 alkyl)amino, C2-C5 cyclic amino or hydrogen.Type: ApplicationFiled: August 28, 2008Publication date: September 23, 2010Applicant: Sumitomoo Chemical Company, LimitedInventors: Koji Kumamoto, Hiroyuki Miyazaki
-
Patent number: 7795448Abstract: Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders.Type: GrantFiled: May 6, 2005Date of Patent: September 14, 2010Assignee: Cytokinetics, IncorporatedInventors: Xiangping Qian, Andrew I. McDonald, Han-Jie Zhou, Luke W. Ashcraft, Bing Yao, Hong Jiang, Jennifer Kuo Chen Huang, Jianchao Wang, David J. Morgans, Jr., Bradley P. Morgan, Gustave Bergnes, Dashyant Dhanak, Steven D. Knight, Nicholas D. Adams, Cynthia A. Parrish, Kevin Duffy, Duke Fitch, Rosanna Tedesco
-
Publication number: 20100222393Abstract: Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.Type: ApplicationFiled: December 21, 2006Publication date: September 2, 2010Inventors: Naresh Kumar, Jaskiran Kaur, Venkata P. Palle, Beenu Bhatt, Shelly Jindal, Anita Chugh, Suman Gupta, Abhijit Ray, Shivani Malhotra, Raj Kumar Shirumalla
-
Publication number: 20100222403Abstract: The present invention encompasses anhydrous micogel formulations containing miconazole and methods of use for the treatment of topical disorders including acne.Type: ApplicationFiled: June 27, 2006Publication date: September 2, 2010Inventors: Marcel Borgers, Valerie Vroome, Geert Cauwenbergh
-
Publication number: 20100215775Abstract: The invention relates to the use of C10-C14-alkane-1,2-diols, in particular 1,2-decanediol, 1,2-dodecanediol and/or 1,2-tetradecanediol, in the preparation of a composition for the prophylaxis and/or treatment of Malassezia-induced dandruff formation, as well as to cosmetic and/or dermatological preparations comprising C10-C14-alkane-1,2-diols.Type: ApplicationFiled: October 12, 2007Publication date: August 26, 2010Applicant: SYMRISE GmbH & Co. KGInventors: Gerhard Schmaus, Sabine Lange
-
Publication number: 20100216784Abstract: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing ?-amyloid production, ?-amyloid deposition, ?-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease ?-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.Type: ApplicationFiled: April 29, 2010Publication date: August 26, 2010Inventors: Michael J. Mullan, Daniel Paris, Pancham Bakshi
-
Patent number: 7776844Abstract: The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system.Type: GrantFiled: April 23, 2009Date of Patent: August 17, 2010Inventors: Ruey J. Yu, Eugene J. Van Scott